Chief Medical Officer (CMO)
Benjamin Zhang, MD
Chief Medical Officer (CMO) of
YD Biopharma, JY Biomedical
Dr. Benjamin Zhang is an accomplished leader in cancer immunotherapy and regenerative medicine, with extensive expertise in immune cell research, stem cell therapy, and clinical trial management. As Chief Medical Officer at YD Biopharma, Dr. Zhang leads initiatives in the development of gamma delta T cell expansion platforms and exosome-based investigational therapies for oncology applications. He also serves as Chief Medical Officer at JY Biomedical, overseeing clinical operations and the advancement of investigational cancer therapies.
“At YD Biopharma, we are committed to translating scientific innovation into tangible patient benefits. Through a focus on collaboration and continuous advancement, we aim to contribute to the future of cancer care and regenerative medicine, bringing new possibilities to patients with unmet medical needs.”
Academic Excellence
M.D., School of Medicine, Taipei Medical University (2017–2023)
Comprehensive training in clinical medicine, research methodologies, and patient-centered care.
Professional Achievements
"METHOD FOR THE PRODUCTION OF GAMMA DELTA T CELLS FOR IMMUNOTHERAPY APPLICATIONS", U.S. Patent Application No.: 63/742,633
Published breakthrough research in high-impact journals like Int J Mol Sci, Cancers, and Biochim Biophys Acta.
Overseeing clinical development and regulatory submissions to support the evaluation of safety and efficacy for investigational cancer therapies.
Entrepreneurial Ventures
YD Biopharma
Advancing the research and development of precision medicine and exosome-based investigational therapies, with a focus on early cancer detection and limbal stem cell exosome therapy.
JY Biomedical
Advancing the research and development of cancer vaccines, cell therapies, and regenerative medicine approaches in collaboration with major partners, including Hexun Biosciences and 3D Global Biotech.
Philanthropy and Leadership
Dr. Zhang is committed to advancing global healthcare and supporting efforts to improve patient outcomes. He actively participates in philanthropic initiatives aimed at expanding access to innovative therapies, with a particular focus on cancer treatment and regenerative medicine.
